Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.

By Dawn L. Hershman, C. Lacchetti, Robert H. Dworkin, Ellen M. Lavoie Smith, J. Bleeker, G. Cavaletti, Cynthia Chauhan, P. Gavin, A. Lavino, M. Lustberg and 8 more. Journal of Clinical Oncology, 2014

996 citations recorded by the source corpus.

Subfields: Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/713fb0cbf6e6570e18a83afaa49053e8a2c1f9a2

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. C. Runowicz
2. C. Leach
3. N. Henry
4. Patricia A. Ganz
5. Karen S Henry
6. H. Mackey
7. R. Cowens-Alvarado
8. Rachel S. Cannady

Citations in the corpus

• American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline (2016, positive): “Where appropriate, this guideline builds upon the recently published ASCO symptom-based guidelines for adult cancer survivors.(14,15,25)”
• Incidence, Prevalence and Predictors of Chemotherapy Induced Peripheral Neuropathy (2016, neutral): “The development of CIPN may require chemotherapy dose reduction or cessation, which can increase cancer-related morbidity and mortality [17,31].”
• Mechanisms of Chemotherapy-Induced Peripheral Neuropathy (2019, background): “There was also a weak recommendation for a topical gel containing baclofen, amitriptyline and ketamine [7,219].”